MRK v. AMGN: A Comparison of R&D Productivity
Summary and Conclusion In light of the recent change in MRK’s R&D leadership, and evidence[1] that the company may be planning a significant change in its approach to R&D, we…
Relative Price and Value of pre-Phase III Pipelines for the 22 Largest Drug & Biotech Companies
Premise and rationale Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of the value of assets that are…
SSR Health’s Hidden Pipeline Analysis: Relative Price and Value of pre-Phase III Pipelines; and Relative Rates of R&D Productivity, for the 23 Largest Drug & Biotech Companies
Premise and rationale behind the ‘Hidden Pipeline’ valuation method Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of…
SSR Index of Drug and Biotech Pipeline Values
Background Product pipelines account for a large percentage of drug and biotech companies’ total values, however relatively little information about pipeline products is available through traditional sources. As a result,…
An Index of the Value in Large Cap PharmaCos’ Mid- to Early-Stage Pipelines
Summary and Investment Conclusion Capital markets can see the characteristics of, and thus place reasonable values on, drug products that are on-market, in registration, or in very late (phase III)…